The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.

Related Articles

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.

Future Oncol. 2018 Feb 16;:

Authors: Amanam I, Gupta R, Mambetsariev I, Salgia R

Abstract
Lung cancer remains the leading cause of cancer deaths in the world with 1.69 million deaths in 2015. A total of 85% of lung cancer cases are non-small-cell lung cancers (NSCLCs). Driver mutations associated with anaplastic lymphoma kinase (ALK) have been identified in a variety of malignancies, including NSCLC. An ALK inhibitor (crizotinib, ceritinib and alectinib) is the preferred therapeutic approach to those advanced ALK fusion variant-positive NSCLC patients. Brigatinib, a next-generation ALK inhibitor, shows promising activity in ALK-rearranged NSCLC that have previously received crizotinib with response rates in ALTA ranging from 42-50%, intracranial response 42-67% and median progression-free survival 9.2-12.9 months. Randomized Phase III trial, ALTA-1 L is investigating brigatinib in ALK inhibitor-naive patients.

PMID: 29451020 [PubMed - as supplied by publisher]

http://ift.tt/2CrINGQ